Species-Selective Pyrimidineamine Inhibitors of Trypanosoma brucei S-Adenosylmethionine Decarboxylase

Oleg A. Volkov, Anthony J. Brockway, Stephen A. Wring, Michael Peel, Zhe Chen, Margaret A. Phillips, Jef K. De Brabander

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

New therapeutic options are needed for treatment of human African trypanosomiasis (HAT) caused by protozoan parasite Trypanosoma brucei. S-Adenosylmethionine decarboxylase (AdoMetDC) is an essential enzyme in the polyamine pathway of T. brucei. Previous attempts to target this enzyme were thwarted by the lack of brain penetration of the most advanced series. Herein, we describe a T. brucei AdoMetDC inhibitor series based on a pyrimidineamine pharmacophore that we identified by target-based high-throughput screening. The pyrimidineamines showed selectivity for T. brucei AdoMetDC over the human enzyme, inhibited parasite growth in whole-cell assay, and had good predicted blood-brain barrier penetration. The medicinal chemistry program elucidated structure-activity relationships within the series. Features of the series that were required for binding were revealed by determining the X-ray crystal structure of TbAdoMetDC bound to one analog. The pyrimidineamine series provides a novel starting point for an anti-HAT lead optimization.

Original languageEnglish (US)
Pages (from-to)1182-1203
Number of pages22
JournalJournal of Medicinal Chemistry
Volume61
Issue number3
DOIs
StatePublished - Feb 8 2018

Fingerprint

Adenosylmethionine Decarboxylase
Trypanosoma brucei brucei
African Trypanosomiasis
Parasites
Enzymes
Pharmaceutical Chemistry
Polyamines
Structure-Activity Relationship
Blood-Brain Barrier
X-Rays
Brain
Growth

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Species-Selective Pyrimidineamine Inhibitors of Trypanosoma brucei S-Adenosylmethionine Decarboxylase. / Volkov, Oleg A.; Brockway, Anthony J.; Wring, Stephen A.; Peel, Michael; Chen, Zhe; Phillips, Margaret A.; De Brabander, Jef K.

In: Journal of Medicinal Chemistry, Vol. 61, No. 3, 08.02.2018, p. 1182-1203.

Research output: Contribution to journalArticle

@article{8ed1274a6d9d4791bb83662a0835e8e1,
title = "Species-Selective Pyrimidineamine Inhibitors of Trypanosoma brucei S-Adenosylmethionine Decarboxylase",
abstract = "New therapeutic options are needed for treatment of human African trypanosomiasis (HAT) caused by protozoan parasite Trypanosoma brucei. S-Adenosylmethionine decarboxylase (AdoMetDC) is an essential enzyme in the polyamine pathway of T. brucei. Previous attempts to target this enzyme were thwarted by the lack of brain penetration of the most advanced series. Herein, we describe a T. brucei AdoMetDC inhibitor series based on a pyrimidineamine pharmacophore that we identified by target-based high-throughput screening. The pyrimidineamines showed selectivity for T. brucei AdoMetDC over the human enzyme, inhibited parasite growth in whole-cell assay, and had good predicted blood-brain barrier penetration. The medicinal chemistry program elucidated structure-activity relationships within the series. Features of the series that were required for binding were revealed by determining the X-ray crystal structure of TbAdoMetDC bound to one analog. The pyrimidineamine series provides a novel starting point for an anti-HAT lead optimization.",
author = "Volkov, {Oleg A.} and Brockway, {Anthony J.} and Wring, {Stephen A.} and Michael Peel and Zhe Chen and Phillips, {Margaret A.} and {De Brabander}, {Jef K.}",
year = "2018",
month = "2",
day = "8",
doi = "10.1021/acs.jmedchem.7b01654",
language = "English (US)",
volume = "61",
pages = "1182--1203",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "3",

}

TY - JOUR

T1 - Species-Selective Pyrimidineamine Inhibitors of Trypanosoma brucei S-Adenosylmethionine Decarboxylase

AU - Volkov, Oleg A.

AU - Brockway, Anthony J.

AU - Wring, Stephen A.

AU - Peel, Michael

AU - Chen, Zhe

AU - Phillips, Margaret A.

AU - De Brabander, Jef K.

PY - 2018/2/8

Y1 - 2018/2/8

N2 - New therapeutic options are needed for treatment of human African trypanosomiasis (HAT) caused by protozoan parasite Trypanosoma brucei. S-Adenosylmethionine decarboxylase (AdoMetDC) is an essential enzyme in the polyamine pathway of T. brucei. Previous attempts to target this enzyme were thwarted by the lack of brain penetration of the most advanced series. Herein, we describe a T. brucei AdoMetDC inhibitor series based on a pyrimidineamine pharmacophore that we identified by target-based high-throughput screening. The pyrimidineamines showed selectivity for T. brucei AdoMetDC over the human enzyme, inhibited parasite growth in whole-cell assay, and had good predicted blood-brain barrier penetration. The medicinal chemistry program elucidated structure-activity relationships within the series. Features of the series that were required for binding were revealed by determining the X-ray crystal structure of TbAdoMetDC bound to one analog. The pyrimidineamine series provides a novel starting point for an anti-HAT lead optimization.

AB - New therapeutic options are needed for treatment of human African trypanosomiasis (HAT) caused by protozoan parasite Trypanosoma brucei. S-Adenosylmethionine decarboxylase (AdoMetDC) is an essential enzyme in the polyamine pathway of T. brucei. Previous attempts to target this enzyme were thwarted by the lack of brain penetration of the most advanced series. Herein, we describe a T. brucei AdoMetDC inhibitor series based on a pyrimidineamine pharmacophore that we identified by target-based high-throughput screening. The pyrimidineamines showed selectivity for T. brucei AdoMetDC over the human enzyme, inhibited parasite growth in whole-cell assay, and had good predicted blood-brain barrier penetration. The medicinal chemistry program elucidated structure-activity relationships within the series. Features of the series that were required for binding were revealed by determining the X-ray crystal structure of TbAdoMetDC bound to one analog. The pyrimidineamine series provides a novel starting point for an anti-HAT lead optimization.

UR - http://www.scopus.com/inward/record.url?scp=85041899302&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041899302&partnerID=8YFLogxK

U2 - 10.1021/acs.jmedchem.7b01654

DO - 10.1021/acs.jmedchem.7b01654

M3 - Article

VL - 61

SP - 1182

EP - 1203

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 3

ER -